ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.

ProKidney is a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), aiming to preserve kidney function in patients who face limited options for care, according to self-described claims.

COM:PROKIDNEY

ProKidney

Last Close

1.74

22/11 21:00

Market Cap

713.55M

Beta: -

Volume Today

370.91K

Avg: -

Financials Not Available